Tacatuzumab tetraxetan
Tacatuzumab tetraxetan (pronunciation: ta-cat-uh-zoo-mab tet-ra-xe-tan) is a monoclonal antibody designed for the treatment of cancer. It is also known as CC49-deltaCH2.
Etymology
The name "Tacatuzumab tetraxetan" is derived from the International Nonproprietary Names (INN), where "taca-" refers to the target, "tuzumab" is a stem used for humanized antibodies, and "tetraxetan" refers to the chelating agent used in the drug.
Mechanism of Action
Tacatuzumab tetraxetan works by binding to the TAG-72 antigen, a protein that is overexpressed in many types of cancer. The tetraxetan component of the drug is a chelating agent that can be used to carry a radioactive isotope, such as yttrium-90, to the cancer cells. This allows for targeted radiation therapy.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Cancer: A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.
- TAG-72: A protein that is overexpressed in many types of cancer.
- Yttrium-90: A radioactive isotope used in cancer treatment.
- Radiation therapy: The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
See Also
External links
- Medical encyclopedia article on Tacatuzumab tetraxetan
- Wikipedia's article - Tacatuzumab tetraxetan
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski